Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daniel Chancellor

Latest From Daniel Chancellor

Juicy Apples Come From Healthy Trees: Advice For Platform Developers

Speaking at BIO-Europe Spring, three leaders of platform life sciences companies offer advice on their scalable and lower risk business models that support innovation within partner biopharma companies.

Innovation Platform Technologies

How COVID-19 Disrupted The Clinical Trial Status Quo

As the world begins its transition into a post-pandemic existence, it becomes possible to look back on the past two years and begin to quantify the effects COVID-19 has brought. For the biopharmaceutical industry, clinical trials have been at the forefront.

Clinical Trials Coronavirus COVID-19

Fresh Recommendations For Rare Disease Trial Sponsors

Best practices to help sponsors design patient-centric studies, build trial awareness among important physician and health care professional groups, leverage advocacy groups to speed up patient recruitment, and ultimately gain a competitive edge in rare disease trial strategies.

Rare Diseases Research & Development

Editing The Future

Gene editing is positioning itself as the latest evolution of genetic therapies and is due for an inflection point in 2022 as a number of milestones will be reached.

Gene Therapy Innovation

Managing Lifecycles Amid Stifling Competition

Biopharma is entering a new period of intense competition from new sources, requiring a change in approach to portfolio strategy and lifecycle management.

Business Strategies Research & Development

Biotech’s Cambrian Explosion

An increasing number of sophisticated tools are on offer to address new therapeutic challenges and remaining unmet needs.

Research & Development Outlook 2022
See All
UsernamePublicRestriction

Register